CCM
FOLD

Consonance Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Consonance Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-507,739
Closed -$4.95M – 34
2019
Q4 		$4.95M Buy
+507,739
New +$4.65M 0.3% 32

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Consonance Capital Management's FOLD Position: Q1 2020 in Review

Consonance Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2020, closing a stake of 507,739 shares — an estimated $4.95M sold.

Consonance Capital Management first reported a position in FOLD in Q4 2019 and held it in 1 quarter. The position peaked at $4.95M in Q4 2019. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2020.

  • Consonance Capital Management reported no remaining Amicus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Consonance Capital Management sold 507,739 Amicus Therapeutics shares in Q1 2020, an estimated $4.95M.
  • Consonance Capital Management first reported a position in Amicus Therapeutics in Q4 2019 and held it in 1 quarter.
  • Consonance Capital Management's Amicus Therapeutics position peaked at $4.95M in Q4 2019.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2020.

Based on Consonance Capital Management's 13F filing for Q1 2020, filed 15 May 2020.